论文部分内容阅读
目的分析继发进展型多发性硬化(SPMS)患者接受自体造血干细胞移植(auto-HSCT)疗效及预后因素分析。方法收集2001—2009年首都医科大学宣武医院收治的36例SPMS患者。粒细胞集落刺激因子(G-CSF)5μg/kg皮下注射4~6 d动员造血干细胞,采集外周血单个核细胞,其中28例患者分选CD34+细胞。预处理方案为BEAM(卡氮芥、马法兰、替尼泊甙及阿糖胞苷)。结果15例临床缓解,5例疾病稳定,14例移植后复发,2例失访。88个月预期无复发存活率55%。发病时有视神经损伤是移植预后不良的危险因素。结论auto-HSCT是SPMS患者获得长期疾病缓解的有效方法,视神经损伤是移植预后不良因素。
Objective To analyze the efficacy and prognostic factors of auto-HSCT in patients with secondary progressive multiple sclerosis (SPMS). Methods Thirty-six patients with SPMS who were admitted to Xuanwu Hospital of Capital Medical University from 2001 to 2009 were collected. G-CSF 5μg / kg subcutaneously 4 to 6 days to mobilize hematopoietic stem cells, peripheral blood mononuclear cells were collected, of which 28 patients were sorted CD34 + cells. The pretreatment regimen is BEAM (Carmustine, melphalan, Teniposide and Cytarabine). Results 15 cases of clinical remission, 5 cases of stable disease, 14 cases of recurrence after transplantation, 2 cases were lost. 88 months expected recurrence-free survival rate of 55%. Ocular optic nerve injury is a risk factor for poor prognosis. Conclusion Auto-HSCT is an effective method for long-term disease relief in patients with SPMS. The optic nerve injury is a poor prognostic factor for the transplantation.